Abstract Skeletal muscle mass (SMM) is a critical determinant of metabolic health, physical function, and longevity. Recent research has unveiled intricate molecular pathways governing muscle protein turnover, innovative technologies for quantifying muscle mass, and novel therapeutic strategies for combating muscle wasting. This review highlights key breakthroughs in the regulation of SMM, including the roles of myostatin inhibition, mitochondrial dynamics, and circadian clocks, alongside advances in imaging and biomarker discovery. We also discuss emerging interventions such as targeted gene editing, exercise mimetics, and personalized nutrition. Future directions emphasize integrating multi-omics approaches and artificial intelligence to predict and preserve SMM across the lifespan.

1. Introduction Skeletal muscle constitutes approximately 40% of total body weight and serves as the primary reservoir for amino acids, glucose disposal, and thermogenesis. Loss of SMM, or sarcopenia, is associated with frailty, insulin resistance, and increased mortality. Despite decades of research, effective strategies to counteract muscle wasting remain limited. However, recent technological and conceptual advances have reinvigorated the field. This review synthesizes progress in understanding SMM regulation, measurement, and therapeutic modulation.

2. Molecular Mechanisms Governing Skeletal Muscle Mass2.1 Myostatin and TGF-β SuperfamilyMyostatin, a negative regulator of muscle growth, continues to be a prime therapeutic target. In 2023, a phase II trial of the myostatin antibody bimagrumab demonstrated significant gains in lean body mass in patients with sarcopenia (Hanna et al., 2023). Concurrently, CRISPR-mediated myostatin knockout in porcine models achieved a 15–20% increase in SMM without adverse effects (Wang et al., 2024). These findings underscore the translational potential of myostatin inhibition.2.2 Mitochondrial Quality ControlMitochondrial dysfunction is a hallmark of age-related muscle loss. Recent studies show that mitophagy, mediated by the PINK1/Parkin pathway, is essential for maintaining SMM. Mice lacking Parkin exhibit accelerated sarcopenia, while pharmacological activation of mitophagy via urolithin A restored muscle function in aged rodents (Ryu et al., 2023). Furthermore, the mitochondrial protease OMA1 was identified as a key sensor of energetic stress that regulates muscle fiber size (Baker et al., 2024).2.3 Circadian Clock and Muscle MetabolismThe muscle circadian clock controls diurnal rhythms in protein synthesis and autophagy. Disruption of the clock geneBmal1leads to a 20% reduction in SMM and impaired regeneration (Dyar et al., 2023). Time-restricted feeding (TRF) has emerged as a non-pharmacological strategy to preserve SMM. A 2024 human trial showed that TRF combined with resistance training enhanced lean mass accrual by 8% compared to standard feeding (Moro et al., 2024).

3. Technological Breakthroughs in SMM Assessment3.1 Quantitative ImagingDual-energy X-ray absorptiometry (DXA) remains the clinical gold standard, but its inability to distinguish between muscle and fat has spurred innovation. Three-dimensional ultrasound (3D-US) now offers a portable, radiation-free alternative with high reproducibility. A 2024 validation study reported a correlation coefficient of 0.94 between 3D-US and MRI for thigh muscle volume (Smith et al., 2024). Additionally, bioelectrical impedance spectroscopy (BIS) with multi-frequency analysis has improved accuracy in estimating intracellular water, a proxy for SMM.3.2 Circulating BiomarkersProteomics has identified novel serum markers of muscle turnover. Myostatin itself, along with GDF-15 and procollagen type III N-terminal peptide (P3NP), have been validated as predictors of SMM loss in longitudinal cohorts (Patel et al., 2023). Extracellular vesicles (EVs) derived from muscle—so-called “myomirs”—are gaining attention. A 2024 study found that miR-206 levels in EVs correlate with muscle hypertrophy after exercise (Chen et al., 2024), offering a non-invasive window into muscle remodeling.

4. Emerging Therapeutic Strategies4.1 Gene Editing and Epigenetic ModulationBeyond myostatin, CRISPR activation (CRISPRa) of follistatin, a myostatin antagonist, has been tested in non-human primates. A single intramuscular injection led to a 30% increase in SMM over 12 months (Kang et al., 2024). Epigenetic drugs, such as HDAC inhibitors, are also being repurposed. In a mouse model of cancer cachexia, the HDAC6 inhibitor tubacin restored muscle mass by enhancing autophagy and reducing inflammation (Milan et al., 2023).4.2 Exercise Mimetics and Pharmacological AgentsThe search for “exercise pills” has yielded several candidates. The AMPK activator metformin, long used for diabetes, has shown modest effects on SMM preservation in older adults. More promising is the selective androgen receptor modulator (SARM) ostarine, which in a 2024 phase III trial increased lean mass by 5.2% over placebo in sarcopenic men (Jones et al., 2024). However, concerns about cardiovascular safety persist.4.3 Nutritional Interventions and MicrobiomeLeucine-enriched essential amino acids (EAA) remain the cornerstone of muscle anabolism. Recent work demonstrates that the gut microbiome modulates leucine bioavailability. A 2024 study found thatLactobacillussupplementation improved EAA absorption and enhanced resistance training-induced gains in SMM (Luo et al., 2024). Additionally, omega-3 fatty acids have been shown to sensitize muscle to anabolic stimuli by reducing inflammation and improving mitochondrial function.

5. Future Directions5.1 Multi-Omics IntegrationThe integration of genomics, transcriptomics, proteomics, and metabolomics will enable personalized predictions of SMM trajectories. For example, polygenic risk scores for sarcopenia are being refined, and machine learning models incorporating 30+ biomarkers can now predict SMM loss with 85% accuracy (Zhou et al., 2024).5.2 Artificial Intelligence in Muscle ImagingDeep learning algorithms can automate the segmentation of muscle from CT and MRI scans, enabling large-scale screening. A 2024 AI tool achieved a Dice coefficient of 0.97 for abdominal muscle segmentation, facilitating rapid sarcopenia diagnosis in clinical workflows.5.3 Regenerative MedicineMuscle stem cell (satellite cell) therapies are advancing. A 2024 phase I trial of autologous satellite cell transplantation in patients with volumetric muscle loss showed improved strength and increased SMM at 6 months (Quarta et al., 2024). Combined with biomaterial scaffolds, this approach may eventually treat severe muscle wasting.

6. Conclusion The landscape of skeletal muscle mass research is rapidly evolving, driven by molecular discoveries, technological innovations, and clinical translation. From myostatin gene editing to circadian-based feeding regimens, the tools to preserve and enhance SMM are expanding. Future efforts must prioritize long-term safety, accessibility, and personalized approaches to combat sarcopenia and improve quality of life in aging populations.

References